Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Larotrectinib (Vitrakvi) is approved for adult and pediatric patients with solid tumors characterized by a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, provided there is no known acquired resistance mutation. It is applicable for cases that are metastatic or unsuitable for surgery due to the high risk of severe morbidity, and for patients who have exhausted all satisfactory alternatives or whose condition has worsened after treatment.
• Three systematic reviews/meta-analyses were examined to collect data on this medication. These studies compared the safety and effectiveness of Vitrakvi with other medications, with a focus on specific population types and subgroup considerations.
• The medication is effective across a range of tumor types, including those not commonly included in clinical trials like central nervous system tumors. This wide-ranging efficacy is vital given the traditionally limited treatment options for these conditions.
• In comparison with entrectinib, another TRK inhibitor for NTRK gene fusion tumors, larotrectinib has a higher objective response rate at 75%, suggesting it may be more effective in stimulating tumor response even though economic or quality of life data are lacking.
• Larotrectinib has proven its effectiveness in both adults and pediatric patients with advanced or metastatic solid tumors. It is also beneficial for subgroups such as individuals with central nervous system tumors, which have been underrepresented in previous studies.
• Despite its notable success, there is a notable lack of economic and quality-of-life data regarding the use of larotrectinib, indicating the need for additional research to fully appreciate the broad impact it can have on patient care.